The Euan MacDonald Centre at the University of Edinburgh has launched a clinical drug trial for Motor Neurone Disease (MND).
The MND-SMART study is seeking MND patients from across the UK to evaluate potential treatments. It aims to enrol as many patients as possible.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trials will be adaptive, allowing researchers to change their approach and test drugs based on emerging results.
Researchers will begin MND-SMART by evaluating the efficacy of licenced drugs on people with MND. The first participants will be tested at the Anne Rowling Regenerative Neurology Clinic in Edinburgh. Several other clinics are expected to join the initiative during the year.
MND-SMART co-investigator Dr Suvankar Pal said: “We are extremely grateful to the people with MND who have helped us design the trial and we believe their involvement will mean far more people will be able to take part.
“Listening to people with MND means we have developed MND-SMART to have very few exclusion criteria.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We have also included the option of video calls to reduce the number of times people have to make the tiring journey to a clinic.”
The trial is funded by investments from MND Scotland, My Name’5 Doddie Foundation, and the Euan MacDonald Centre for MND Research, as well as private donations.
Specialists from the University College London and the University of Warwick are also associated with the trial.
The Euan MacDonald Centre for Motor Neurone Disease Research is a non-profit, charitable network engaged in improving the lives of patients living with MND.
